{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T05:39:23Z","timestamp":1777700363004,"version":"3.51.4"},"reference-count":59,"publisher":"IMR Press","issue":"4","license":[{"start":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T00:00:00Z","timestamp":1776816000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100006769","name":"Russian Science Foundation","doi-asserted-by":"crossref","award":["24-15-00097"],"award-info":[{"award-number":["24-15-00097"]}],"id":[{"id":"10.13039\/501100006769","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Front. Biosci. (Landmark Ed)"],"abstract":"<jats:p>Background: Neuroblastoma (NB), a transcriptionally driven pediatric malignancy, exhibits a remarkable clinical and biological heterogeneity. Two major subtypes, adrenergic and mesenchymal, are differentially governed by distinct subsets of transcription factors that constitute the core regulatory circuitry (CRC). The adrenergic subtype is often associated with MYCN oncogene amplification and is particularly aggressive and therapy-resistant, underscoring the need for novel therapeutic targets. Methods: Gene knockdown with siRNAs, qRT-PCR, flow cytometry-assisted measurements of intracellular oxidation and cell death parameters, immunoblotting, cytotoxicity assays (MTT, colony formation). Results: We identified the multifunctional non-POU domain-containing octamer-binding (NONO) protein as a guardian of individual CRC genes, thereby promoting the survival of NB cells with different MYCN copy numbers. In the MYCN-amplified Kelly cell line, intracellular oxidation induced by auranofin, an inhibitor of thioredoxin reductase 1 (TrxR1), rapidly down-regulated NONO mRNA and protein levels. Conversely, NONO knockdown by RNA interference (siNONO) also triggered intracellular oxidation. These effects were less pronounced in the SK-N-AS cell line carrying a single MYCN copy, as well as in non-malignant HS5 fibroblasts. In Kelly and IMR-32 cells, siNONO attenuated auranofin-induced activation of CRC genes, namely, heart and neural crest derivatives expressed 2 (HAND2) and paired-like homeobox 2B (PHOX2B). Furthermore, the Kelly cells were more sensitive to combinations of sublethal auranofin concentrations and siNONO than the counterparts with single MYCN copy. Importantly, MYCN-amplified cells demonstrated a significantly suppressed clonogenic survival 14 days after transient exposure to these combinations compared with each agent alone\u037e HS5 fibroblasts were largely spared. Conclusions: Our findings reveal a new role for the transcriptional regulator NONO in maintenance of the cellular redox balance and justify the strategy of therapeutic targeting of MYCN-amplified tumors vulnerable to oxidative stress.<\/jats:p>","DOI":"10.31083\/fbl48544","type":"journal-article","created":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T09:29:27Z","timestamp":1777454967000},"source":"Crossref","is-referenced-by-count":0,"title":["Inactivation of NONO by Auranofin or RNA Interference Triggers Lethal Oxidative Stress in Neuroblastoma Cells"],"prefix":"10.31083","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-9512-8599","authenticated-orcid":true,"given":"Sofya S.","family":"Pogodaeva","sequence":"first","affiliation":[{"name":"Center for Molecular and Biological Technologies, ITMO University, 190002 Saint Petersburg, Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-7200-0117","authenticated-orcid":true,"given":"Olga O.","family":"Miletina","sequence":"additional","affiliation":[{"name":"Center for Molecular and Biological Technologies, ITMO University, 190002 Saint Petersburg, Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-6561-6594","authenticated-orcid":true,"given":"Lidia V.","family":"Mammadova","sequence":"additional","affiliation":[{"name":"Center for Molecular and Biological Technologies, ITMO University, 190002 Saint Petersburg, Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5799-7767","authenticated-orcid":true,"given":"Nadezhda V.","family":"Antipova","sequence":"additional","affiliation":[{"name":"Laboratory of Membrane Bioenergetics, Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, 117997 Moscow, Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6469-0221","authenticated-orcid":true,"given":"Alexander A.","family":"Shtil","sequence":"additional","affiliation":[{"name":"Laboratory of Tumor Cell Death, Blokhin National Medical Research Center of Oncology, 115522 Moscow, Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3700-4131","authenticated-orcid":true,"given":"Oleg A.","family":"Kuchur","sequence":"additional","affiliation":[{"name":"Center for Molecular and Biological Technologies, ITMO University, 190002 Saint Petersburg, Russia"},{"name":"Laboratory for Bio and Chemoinformatics, School of Computer Science, Physics and Technology, Higher School of Economics, 194100 Saint Petersburg, Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"16242","published-online":{"date-parts":[[2026,4,22]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","unstructured":"Tomolonis JA, Agarwal S, Shohet JM. Neuroblastoma pathogenesis: deregulation of embryonic neural crest development. Cell and Tissue Research. 2018; 372: 245\u2013262.","DOI":"10.1007\/s00441-017-2747-0"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"Lundberg KI, Treis D, Johnsen JI. Neuroblastoma Heterogeneity, Plasticity, and Emerging Therapies. Current Oncology Reports. 2022; 24: 1053\u20131062.","DOI":"10.1007\/s11912-022-01270-8"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"Brodeur GM. Spontaneous regression of neuroblastoma. Cell and Tissue Research. 2018; 372: 277\u2013286.","DOI":"10.1007\/s00441-017-2761-2"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"Qiu B, Matthay KK. Advancing therapy for neuroblastoma. Nature Reviews. Clinical Oncology. 2022; 19: 515\u2013533.","DOI":"10.1038\/s41571-022-00643-z"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"Lerone M, Ognibene M, Pezzolo A, Martucciello G, Zara F, Morini M, et al. Molecular Genetics in Neuroblastoma Prognosis. Children. 2021; 8: 456.","DOI":"10.3390\/children8060456"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"M\u00fcller M, Trunk K, Fleischhauer D, B\u00fcchel G. MYCN in neuroblastoma: The kings\u2019 new clothes and drugs. EJC Paediatric Oncology. 2024; 4: 100182.","DOI":"10.1016\/j.ejcped.2024.100182"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"Pastorino F, Capasso M, Brignole C, Lasorsa VA, Bensa V, Perri P, et al. Therapeutic Targeting of ALK in Neuroblastoma: Experience of Italian Precision Medicine in Pediatric Oncology. Cancers. 2023; 15: 560.","DOI":"10.3390\/cancers15030560"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"Car\u00e9n H, Kryh H, Nethander M, Sj\u00f6berg RM, Tr\u00e4ger C, Nilsson S, et al. High-risk neuroblastoma tumors with 11q-deletion display a poor prognostic, chromosome instability phenotype with later onset. Proceedings of the National Academy of Sciences of the United States of America. 2010; 107: 4323\u20134328.","DOI":"10.1073\/pnas.0910684107"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"Comitani F, Nash JO, Cohen-Gogo S, Chang AI, Wen TT, Maheshwari A, et al. Diagnostic classification of childhood cancer using multiscale transcriptomics. Nature Medicine. 2023; 29: 656\u2013666.","DOI":"10.1038\/s41591-023-02221-x"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"Sengupta S, Das S, Crespo AC, Cornel AM, Patel AG, Mahadevan NR, et al. Mesenchymal and adrenergic cell lineage states in neuroblastoma possess distinct immunogenic phenotypes. Nature Cancer. 2022; 3: 1228\u20131246.","DOI":"10.1038\/s43018-022-00427-5"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"Vayani OR, Kaufman ME, Moore K, Chennakesavalu M, TerHaar R, Chaves G, et al. Adrenergic and mesenchymal signatures are identifiable in cell-free DNA and correlate with metastatic disease burden in children with neuroblastoma. Pediatr Blood & Cancer. 2024; 71: e30735.","DOI":"10.1002\/pbc.30735"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"Wang L, Tan TK, Durbin AD, Zimmerman MW, Abraham BJ, Tan SH, et al. ASCL1 is a MYCN- and LMO1-dependent member of the adrenergic neuroblastoma core regulatory circuitry. Nature Communications. 2019; 10: 5622.","DOI":"10.1038\/s41467-019-13515-5"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"Shendy NAM, Zimmerman MW, Abraham BJ, Durbin AD. Intrinsic transcriptional heterogeneity in neuroblastoma guides mechanistic and therapeutic insights. Cell Reports. Medicine. 2022; 3: 100632.","DOI":"10.1016\/j.xcrm.2022.100632"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"Boeva V, Louis-Brennetot C, Peltier A, Durand S, Pierre-Eug\u00e8ne C, Raynal V, et al. Heterogeneity of neuroblastoma cell identity defined by transcriptional circuitries. Nature Genetics. 2017; 49: 1408\u20131413.","DOI":"10.1038\/ng.3921"},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"Naiditch JA, Jie C, Lautz TB, Yu S, Clark S, Voronov D, et al. Mesenchymal change and drug resistance in neuroblastoma. The Journal of Surgical Research. 2015; 193: 279\u2013288.","DOI":"10.1016\/j.jss.2014.07.018"},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"van Groningen T, Akogul N, Westerhout EM, Chan A, Hasselt NE, Zwijnenburg DA, et al. A NOTCH feed-forward loop drives reprogramming from adrenergic to mesenchymal state in neuroblastoma. Nature Communications. 2019; 10: 1530.","DOI":"10.1038\/s41467-019-09470-w"},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"Durbin AD, Versteeg R. Cell state plasticity in neuroblastoma. EJC Paediatric Oncology. 2024; 4: 100184.","DOI":"10.1016\/j.ejcped.2024.100184"},{"key":"ref18","doi-asserted-by":"publisher","unstructured":"Thirant C, Peltier A, Durand S, Kramdi A, Louis-Brennetot C, Pierre-Eug\u00e8ne C, et al. Reversible transitions between noradrenergic and mesenchymal tumor identities define cell plasticity in neuroblastoma. Nature Communications. 2023; 14: 2575.","DOI":"10.1038\/s41467-023-38239-5"},{"key":"ref19","doi-asserted-by":"publisher","unstructured":"Krystal J, Foster JH. Treatment of High-Risk Neuroblastoma. Children. 2023; 10: 1302.","DOI":"10.3390\/children10081302"},{"key":"ref20","doi-asserted-by":"publisher","unstructured":"Wawrzuta D, Chojnacka M, Dembowska-Bagi\u0144ska B, Raciborska A, Hutnik \u0141, Cie\u015blak M, et al. Revisiting the role of radiotherapy in the treatment of neuroblastoma 4S: 30 years of institutional experience and systematic review. Clinical and Translational Radiation Oncology. 2024; 47: 100791.","DOI":"10.1016\/j.ctro.2024.100791"},{"key":"ref21","doi-asserted-by":"publisher","unstructured":"Sait S, Modak S. Anti-GD2 immunotherapy for neuroblastoma. Expert Review of Anticancer Therapy. 2017; 17: 889\u2013904.","DOI":"10.1080\/14737140.2017.1364995"},{"key":"ref22","doi-asserted-by":"publisher","unstructured":"London WB, Castel V, Monclair T, Ambros PF, Pearson ADJ, Cohn SL, et al. Clinical and biologic features predictive of survival after relapse of neuroblastoma: a report from the International Neuroblastoma Risk Group project. Journal of Clinical Oncology. 2011; 29: 3286\u20133292.","DOI":"10.1200\/JCO.2010.34.3392"},{"key":"ref23","doi-asserted-by":"publisher","unstructured":"Herd F, Basta NO, McNally RJQ, Tweddle DA. A systematic review of re-induction chemotherapy for children with relapsed high-risk neuroblastoma. European Journal of Cancer. 2019; 111: 50\u201358.","DOI":"10.1016\/j.ejca.2018.12.032"},{"key":"ref24","doi-asserted-by":"publisher","unstructured":"Fawzy M, Hamoda A, Elhemaly A, Elkinaai N, Soliman S, Reda H, et al. Does Salvage Chemotherapy Regimen Intensity Embark on Clearance of Bone Marrow Neuroblastoma? Asian Pacific Journal of Cancer Prevention. 2019; 20: 1519\u20131524.","DOI":"10.31557\/APJCP.2019.20.5.1519"},{"key":"ref25","doi-asserted-by":"publisher","unstructured":"Zhou X, Wang X, Li N, Guo Y, Yang X, Lei Y. Therapy resistance in neuroblastoma: Mechanisms and reversal strategies. Frontiers in Pharmacology. 2023; 14: 1114295.","DOI":"10.3389\/fphar.2023.1114295"},{"key":"ref26","doi-asserted-by":"publisher","unstructured":"Y KN, Arjunan A, Maigandan D, Dharmarajan A, Perumalsamy LR. Advances and challenges in therapeutic resistant biomarkers of neuroblastoma: A comprehensive review. Biochimica et Biophysica Acta. Reviews on Cancer. 2024; 1879: 189222.","DOI":"10.1016\/j.bbcan.2024.189222"},{"key":"ref27","doi-asserted-by":"publisher","unstructured":"Durbin AD, Zimmerman MW, Dharia NV, Abraham BJ, Iniguez AB, Weichert-Leahey N, et al. Selective gene dependencies in MYCN-amplified neuroblastoma include the core transcriptional regulatory circuitry. Nature Genetics. 2018; 50: 1240\u20131246.","DOI":"10.1038\/s41588-018-0191-z"},{"key":"ref28","doi-asserted-by":"publisher","unstructured":"Ciaccio R, De Rosa P, Aloisi S, Viggiano M, Cimadom L, Zadran SK, et al. Targeting Oncogenic Transcriptional Networks in Neuroblastoma: From N-Myc to Epigenetic Drugs. International Journal of Molecular Sciences. 2021; 22: 12883.","DOI":"10.3390\/ijms222312883"},{"key":"ref29","doi-asserted-by":"publisher","unstructured":"Gao Y, Volegova M, Nasholm N, Das S, Kwiatkowski N, Abraham BJ, et al. Synergistic Anti-Tumor Effect of Combining Selective CDK7 and BRD4 Inhibition in Neuroblastoma. Frontiers in Oncology. 2022; 11: 773186.","DOI":"10.3389\/fonc.2021.773186"},{"key":"ref30","doi-asserted-by":"publisher","unstructured":"Kuchur OA, Pogodaeva SS, Zhdankina VI, Scherbakova AV, Shtil AA, Antipova NV. Targeting transcription in neuroblastoma: focus on the core regulatory circuit. Expert Opinion on Therapeutic Targets. 2025; 29: 579\u2013595.","DOI":"10.1080\/14728222.2025.2545837"},{"key":"ref31","doi-asserted-by":"publisher","unstructured":"Pogodaeva SS, Miletina OO, Antipova NV, Shtil AA, Kuchur OA. Saying \u201cYes\u201d to NONO: A Therapeutic Target for Neuroblastoma and Beyond. Cancers. 2025; 17: 3228.","DOI":"10.3390\/cancers17193228"},{"key":"ref32","doi-asserted-by":"publisher","unstructured":"Ronchetti D, Traini V, Silvestris I, Fabbiano G, Passamonti F, Bolli N, et al. The pleiotropic nature of NONO, a master regulator of essential biological pathways in cancers. Cancer Gene Therapy. 2024; 31: 984\u2013994.","DOI":"10.1038\/s41417-024-00763-x"},{"key":"ref33","doi-asserted-by":"publisher","unstructured":"Zhang S, Cooper JA, Chong YS, Naveed A, Mayoh C, Jayatilleke N, et al. NONO enhances mRNA processing of super-enhancer-associated GATA2 and HAND2 genes in neuroblastoma. EMBO Reports. 2023; 24: e54977.","DOI":"10.15252\/embr.202254977"},{"key":"ref34","doi-asserted-by":"publisher","unstructured":"Liu PY, Erriquez D, Marshall GM, Tee AE, Polly P, Wong M, et al. Effects of a novel long noncoding RNA, lncUSMycN, on N-Myc expression and neuroblastoma progression. Journal of the National Cancer Institute. 2014; 106: dju113.","DOI":"10.1093\/jnci\/dju113"},{"key":"ref35","doi-asserted-by":"publisher","unstructured":"Kathman SG, Koo SJ, Lindsey GL, Her HL, Blue SM, Li H, et al. Remodeling oncogenic transcriptomes by small molecules targeting NONO. Nature Chemical Biology. 2023; 19: 825\u2013836.","DOI":"10.1038\/s41589-023-01270-0"},{"key":"ref36","doi-asserted-by":"publisher","unstructured":"Lindsey GL, Hockley TK, Gomez AV, Marshall AC, Brothers WR, Finney CT, et al. Structural and mechanistic analysis of covalent ligands targeting the RNA-binding protein NONO. Cell Chemical Biology. 2026; 33: 256\u2013267.e11.","DOI":"10.1016\/j.chembiol.2025.12.010"},{"key":"ref37","doi-asserted-by":"publisher","unstructured":"Florio AV, Bur\u00e9 C, Fribourg S. Structural basis for NONO-specific modification by the \u03b1-chloroacetamide compound (R)-SKBG-1. Cell Chemical Biology. 2026; 33: 268\u2013275.e3.","DOI":"10.1016\/j.chembiol.2025.12.013"},{"key":"ref38","doi-asserted-by":"publisher","unstructured":"Abdalbari FH, Telleria CM. The gold complex auranofin: new perspectives for cancer therapy. Discover Oncology. 2021; 12: 42.","DOI":"10.1007\/s12672-021-00439-0"},{"key":"ref39","doi-asserted-by":"publisher","unstructured":"Chmelyuk N, Kordyukova M, Sorokina M, Sinyavskiy S, Meshcheryakova V, Belousov V, et al. Inhibition of Thioredoxin-Reductase by Auranofin as a Pro-Oxidant Anticancer Strategy for Glioblastoma: In Vitro and In Vivo Studies. International Journal of Molecular Sciences. 2025; 26: 2084.","DOI":"10.3390\/ijms26052084"},{"key":"ref40","doi-asserted-by":"publisher","unstructured":"Ma\u00f1as A, Seger A, Adamska A, Smyrilli K, Siaw JT, Radke K, et al. Targeted ferroptosis induction enhances chemotherapy efficacy in chemoresistant neuroblastoma. NPJ Precision Oncology. 2025; 9: 311.","DOI":"10.1038\/s41698-025-01090-6"},{"key":"ref41","doi-asserted-by":"publisher","unstructured":"Madeira JM, Bajwa E, Stuart MJ, Hashioka S, Klegeris A. Gold drug auranofin could reduce neuroinflammation by inhibiting microglia cytotoxic secretions and primed respiratory burst. Journal of Neuroimmunology. 2014; 276: 71\u201379.","DOI":"10.1016\/j.jneuroim.2014.08.615"},{"key":"ref42","doi-asserted-by":"publisher","unstructured":"Floros KV, Cai J, Jacob S, Kurupi R, Fairchild CK, Shende M, et al. MYCN-Amplified Neuroblastoma Is Addicted to Iron and Vulnerable to Inhibition of the System Xc-\/Glutathione Axis. Cancer Research. 2021; 81: 1896\u20131908.","DOI":"10.1158\/0008-5472.CAN-20-1641"},{"key":"ref43","doi-asserted-by":"publisher","unstructured":"Hou GX, Liu PP, Zhang S, Yang M, Liao J, Yang J, et al. Elimination of stem-like cancer cell side-population by auranofin through modulation of ROS and glycolysis. Cell Death & Disease. 2018; 9: 89.","DOI":"10.1038\/s41419-017-0159-4"},{"key":"ref44","doi-asserted-by":"publisher","unstructured":"Gomez RL, Woods LM, Ramachandran R, Abou Tayoun AN, Philpott A, Ali FR. Super-enhancer associated core regulatory circuits mediate susceptibility to retinoic acid in neuroblastoma cells. Frontiers in Cell and Developmental Biology. 2022; 10: 943924.","DOI":"10.3389\/fcell.2022.943924"},{"key":"ref45","doi-asserted-by":"publisher","unstructured":"Kim SJ, Ju JS, Kang MH, Eun JW, Kim YH, Raninga PV, et al. RNA-binding protein NONO contributes to cancer cell growth and confers drug resistance as a theranostic target in TNBC. Theranostics. 2020; 10: 7974\u20137992.","DOI":"10.7150\/thno.45037"},{"key":"ref46","doi-asserted-by":"publisher","unstructured":"Aboelella NS, Brandle C, Kim T, Ding ZC, Zhou G. Oxidative Stress in the Tumor Microenvironment and Its Relevance to Cancer Immunotherapy. Cancers. 2021; 13: 986.","DOI":"10.3390\/cancers13050986"},{"key":"ref47","doi-asserted-by":"publisher","unstructured":"Cockfield JA, Schafer ZT. Antioxidant Defenses: A Context-Specific Vulnerability of Cancer Cells. Cancers. 2019; 11: 1208.","DOI":"10.3390\/cancers11081208"},{"key":"ref48","doi-asserted-by":"publisher","unstructured":"Kim H, Xue X. Detection of Total Reactive Oxygen Species in Adherent Cells by 2\u2032,7\u2032-Dichlorodihydrofluorescein Diacetate Staining. Journal of Visualized Experiments. 2020.","DOI":"10.3791\/60682"},{"key":"ref49","doi-asserted-by":"publisher","unstructured":"Ben Mrid R, El Guendouzi S, Mineo M, El Fatimy R. The emerging roles of aberrant alternative splicing in glioma. Cell Death Discovery. 2025; 11: 50.","DOI":"10.1038\/s41420-025-02323-0"},{"key":"ref50","doi-asserted-by":"publisher","unstructured":"Veas-Perez de Tudela M, Delgado-Esteban M, Cuende J, Bola\u00f1os JP, Almeida A. Human neuroblastoma cells with MYCN amplification are selectively resistant to oxidative stress by transcriptionally up-regulating glutamate cysteine ligase. Journal of Neurochemistry. 2010; 113: 819\u2013825.","DOI":"10.1111\/j.1471-4159.2010.06648.x"},{"key":"ref51","doi-asserted-by":"publisher","unstructured":"Naveed A. Understanding the Role of RNA-Binding Protein NONO and Its Long Non-Coding RNA Target NEAT1 in Driving Progression of Neuroblastoma [PhD dissertation]. Australia: The University of Western Australia. 2020.","DOI":"10.26182\/5f3f662e6ffdc"},{"key":"ref52","doi-asserted-by":"publisher","unstructured":"Onodera T, Momose I, Kawada M. Potential Anticancer Activity of Auranofin. Chemical & Pharmaceutical Bulletin. 2019; 67: 186\u2013191.","DOI":"10.1248\/cpb.c18-00767"},{"key":"ref53","doi-asserted-by":"publisher","unstructured":"Roder C, Thomson MJ. Auranofin: repurposing an old drug for a golden new age. Drugs in R&D. 2015; 15: 13\u201320.","DOI":"10.1007\/s40268-015-0083-y"},{"key":"ref54","doi-asserted-by":"publisher","unstructured":"Bonner MY, Vancsik T, Oliveira-Coelho A, Sabatier P, Beusch CM, Zeqiraj K, et al. Anti-Tumoral Treatment with Thioredoxin Reductase 1 Inhibitor Auranofin Fosters Regulatory T Cell and B16F10 Expansion in Mice. Antioxidants. 2025; 14: 1351.","DOI":"10.3390\/antiox14111351"},{"key":"ref55","doi-asserted-by":"publisher","unstructured":"Chen X, Zhou HJ, Huang Q, Lu L, Min W. Novel action and mechanism of auranofin in inhibition of vascular endothelial growth factor receptor-3-dependent lymphangiogenesis. Anti-cancer Agents in Medicinal Chemistry. 2014; 14: 946\u2013954.","DOI":"10.2174\/1871520614666140610102651"},{"key":"ref56","doi-asserted-by":"publisher","unstructured":"Spadoni C. Pediatric Drug Development: Challenges and Opportunities. Current Therapeutic Research, Clinical and Experimental. 2019; 90: 119\u2013122.","DOI":"10.1016\/j.curtheres.2018.12.001"},{"key":"ref57","doi-asserted-by":"publisher","unstructured":"Hua Y, Dai X, Xu Y, Xing G, Liu H, Lu T, et al. Drug repositioning: Progress and challenges in drug discovery for various diseases. European Journal of Medicinal Chemistry. 2022; 234: 114239.","DOI":"10.1016\/j.ejmech.2022.114239"},{"key":"ref58","doi-asserted-by":"publisher","unstructured":"Novotny NM, Grosfeld JL, Turner KE, Rescorla FJ, Pu X, Klaunig JE, et al. Oxidative status in neuroblastoma: a source of stress? Journal of Pediatric Surgery. 2008; 43: 330\u2013334.","DOI":"10.1016\/j.jpedsurg.2007.10.040"},{"key":"ref59","doi-asserted-by":"publisher","unstructured":"\u010cipak Ga\u0161parovi\u0107 A, Milkovi\u0107 L, Dandachi N, Stanzer S, Pezdirc I, Vran\u010di\u0107 J, et al. Chronic Oxidative Stress Promotes Molecular Changes Associated with Epithelial Mesenchymal Transition, NRF2, and Breast Cancer Stem Cell Phenotype. Antioxidants. 2019; 8: 633.","DOI":"10.3390\/antiox8120633"}],"container-title":["Frontiers in Bioscience-Landmark"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.imrpress.com\/journal\/FBL\/31\/4\/10.31083\/FBL48544","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T09:30:21Z","timestamp":1777455021000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.imrpress.com\/journal\/FBL\/31\/4\/10.31083\/FBL48544"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,22]]},"references-count":59,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026]]}},"alternative-id":["S2768-6701(26)02086-1"],"URL":"https:\/\/doi.org\/10.31083\/fbl48544","relation":{},"ISSN":["2768-6701","2768-6698"],"issn-type":[{"value":"2768-6701","type":"print"},{"value":"2768-6698","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,22]]},"article-number":"48544"}}